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O B J E C T I V E S We conducted a pilot study for a large deﬁnitive clinical trial evaluating the impact of
ranolazine in women with angina, evidence of myocardial ischemia, and no obstructive coronary artery disease
(CAD).
B A C KG ROUND Womenwith angina, evidence ofmyocardial ischemia, but no obstructive CAD frequently
have microvascular coronary dysfunction. The impact of ranolazine in this patient group is unknown.
METHOD S A pilot randomized, double-blind, placebo-controlled, crossover trial was conducted in
20 women with angina, no obstructive CAD, and 10% ischemic myocardium on adenosine stress
cardiac magnetic resonance (CMR) imaging. Participants were assigned to ranolazine or placebo for 4
weeks separated by a 2-week washout. The Seattle Angina Questionnaire and CMR were evaluated after
each treatment. Invasive coronary ﬂow reserve (CFR) was available in patients who underwent clinically
indicated coronary reactivity testing. CMR data analysis included the percentage of ischemic myocar-
dium and quantitative myocardial perfusion reserve index (MPRI).
R E S U L T S Themean age of subjects was 57 11 years. Compared with placebo, patients on ranolazine had
signiﬁcantly higher (better) Seattle AnginaQuestionnaire scores, including physical functioning (p 0.046), angina
stability (p 0.008), and quality of life (p 0.021). There was a trend toward a higher (better) CMRmid-ventricular
MPRI (2.4 [2.0 minimum, 2.8 maximum] vs. 2.1 [1.7 minimum, 2.5 maximum], p  0.074) on ranolazine. Among
women with coronary reactivity testing (n  13), those with CFR 3.0 had a signiﬁcantly improved MPRI on
ranolazine versus placebo compared to women with CFR 3.0 (∆ in MPRI 0.48 vs. 0.82, p  0.04).
CONC L U S I O N S In women with angina, evidence of ischemia, and no obstructive CAD, this pilot
randomized, controlled trial revealed that ranolazine improves angina. Myocardial ischemia may also
improve, particularly among women with low CFR. These data document approach feasibility and
provide outcome variability estimates for planning a deﬁnitive large clinical trial to evaluate the role of
ranolazine in women with microvascular coronary dysfunction. (Microvascular Coronary Disease In
Women: Impact Of Ranolazine; NCT00570089). (J Am Coll Cardiol Img 2011;4:514–22) © 2011 by the
American College of Cardiology Foundation
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omen with angina, evidence of isch-
emia by stress testing, and no obstruc-
tive coronary artery disease (CAD) by
angiography frequently have microvascu-
ar coronary dysfunction (MCD), which carries an
dverse prognosis for cardiovascular events includ-
ng myocardial infarction, stroke, heart failure, and
udden cardiac death (1–3). Patients with MCD
se more healthcare resources and have higher
ealthcare costs similar to those for obstructive
AD; there are an estimated 2 to 3 million women
n the United States with MCD. Persistent angina
espite treatment with nitrates, beta-blockers, and
alcium channel blockers in this patient population
s a therapeutic challenge. Ranolazine is a newer
.S. Food and Drug Administration–approved
edication for treatment of angina, and several
linical trials have demonstrated the safety and
fficacy of ranolazine as an antianginal agent
4 –10). Studies to date have not clearly demon-
trated in a controlled fashion whether the anti-
nginal effect of ranolazine is due to an anti-
schemic mechanism.
Previous work in patients with cardiac syndrome
has demonstrated that adenosine stress perfusion
ardiac magnetic resonance (CMR) is often abnor-
al with a circumferential subendocardial hypoper-
usion pattern (11). Additional work suggests that
tress CMR can differentiate ischemia due to he-
odynamically significant stenosis in a major epi-
ardial artery versus nonsegmental etiologies based
n the pattern of hypoperfusion (12,13).
We conducted a pilot study of ranolazine in
omen with angina, evidence of myocardial isch-
mia by CMR, and no obstructive CAD to docu-
ent feasibility of this approach and to collect data
n outcome variability for the purpose of planning
large definitive clinical trial.
Qualifying 
CMR 
Baseline SAQ 
& DASI
Enrollment & 
Randomization
Treatment Period 1
Up to 24 Months 4 Weeks
Figure 1. Study Design Flow Diagram
Treatment periods 1 and 2: randomized to sequence of ranolazine
magnetic resonance; DASI  Duke Activity Score Index; SAQ  SeattleM E T H O D S
Patient population. Inclusion criteria included
women with signs and symptoms of myocardial
ischemia (chest pain and abnormal routine stress
testing) and no obstructive CAD (50% epicardial
coronary stenosis in all epicardial coronary arteries) on
clinically indicated coronary angiography, who had an
abnormal adenosine stress CMR (10% ischemic
myocardium) within the previous 12 months were
enrolled. No intercurrent cardiac events occurred be-
tween the qualifying CMR scan and trial enrollment
and completion. Exclusion criteria were: 1) contrain-
dications to withholding nitrates, calcium channel
agents, and alpha and beta-adrenergic blockers for
24 h before testing; 2) contraindications to CMR
including implantable cardioverter-defibrillators,
pacemakers, and severe claustrophobia; 3) hepatic
insufficiency, prolonged QT, renal failure; 4)
use of drugs that inhibit CYP3A such as
diltiazem, verapamil, ketoconazole, macro-
lides, and HIV protease inhibitors; 5)
women younger than 18 years of age (3
women of child-bearing age were enrolled),
pregnant, or breastfeeding; 6) women taking
drugs that prolong the QT interval; and 7)
life expectancy 6 months. The Institu-
tional Review Board at Cedars-Sinai Med-
ical Center approved the study, and all
subjects gave written informed consent be-
fore study participation.
Study design. Eligible women had base-
line screening 12-lead electrocardiogram
and blood chemistry for creatinine and
glomerular filtration rate. The study was a
double-blind, placebo-controlled, cross-
over design in which treatment order to ranolazine
and placebo was randomly assigned (Fig. 1). After
enrollment in the study, participants were randomly
CMR, SAQ,
& DASI
CMR, SAQ,
& DASI
ashout Treatment Period 2
 Weeks 4 Weeks
followed by crossover to placebo or vice versa. CMR  cardiac
A B B
A N D
CAD
CFR
CMR
reson
CRT
testin
DASI
Index
MCD
dysfu
MPRI
reserv
SAQ
QuestW
2
ﬁrst
Angina Questionnaire.R E V I A T I O N S
A C R O N YM S
coronary artery disease
coronary flow reserve
cardiac magnetic
ance
coronary reactivity
g
 Duke Activity Status
microvascular coronary
nction
myocardial perfusion
e index
Seattle Angina
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516assigned to ranolazine or placebo for 4 weeks
followed by a 2-week washout. Participants then
crossed over to the alternative study medication for
the second 4-week treatment period. The partic-
ipant’s usual antianginal medication regimen was
continued unchanged throughout study duration.
Women randomized to ranolazine received 500
mg orally twice daily for 2 weeks, and the dose
was increased to 1,000 mg twice daily for an
additional 2 weeks if tolerated. All patients tol-
erated the 500-mg dosing, whereas 2 patients did
not tolerate the 1,000-mg dosing because of GI
side effects, and their dose was reduced. All
participants completed baseline demographic and
health history questionnaires, including the Se-
attle Angina Questionnaire (SAQ) and Duke
Activity Status Index (DASI). The SAQ and
DASI were administered and CMR was per-
formed at the end of each 4-week treatment
period. The SAQ is a self-administered, 19-item
questionnaire that is well validated and sensitive
to clinical changes in stable coronary heart dis-
ease patients (14). The DASI is a 12-item self-
Figure 2. Case Example
Cardiac magnetic resonance images acquired during rest (A) and st
in the anterolateral and inferolateral walls (arrows) at the mid-vent
CMR images show signiﬁcant improvement in the areas of hypoperfusioadministered questionnaire that has also been
validated as a measure of functional capacity (15).
Cardiac magnetic resonance. All CMR studies were
performed with a 1.5-T magnet (Siemens Sonata,
Erlangen, Germany) with electrocardiogram gating
and a phased array coil using a highly standardized
protocol with 0.05 mmol/kg gadolinium first-pass
perfusion 3 slice stress, followed by rest first-pass
perfusion. Left ventricular ejection fraction and wall
motion were evaluated using cine imaging, which was
performed in left ventricular short-axis slices from the
base to the apex. Delayed enhancement imaging was
performed to evaluate for scar. The dose of adenosine
stress (140g/kg1/min1 over 5 min) was consistent
for all studies. All patients tolerated adenosine stress.
CMR was performed approximately 4 h after the
morning dose of study drug, at the same time of day
with identical fasting state, adenosine and gadolinium
dosing infusion protocols, and magnet settings. A repre-
sentative case example of a subject CMR on placebo and
on ranolazine is shown in Figure 2.
The presence and percentage of myocardial hy-
poperfusion were defined semiquantitatively by 2
(B) on placebo, depicting ﬁrst-pass subendocardial hypoperfusion
ar level. After treatment with ranolazine, rest (C) and stress (D)ress
riculn (arrows) at the mid-ventricular level.
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517experienced readers (D.B. and L.T.) who were
blinded to the clinical status of the patients using the
National Heart, Lung and Blood Institute (NHLBI)–
sponsored Women’s Ischemia Syndrome Evaluation
(WISE) CMR core laboratory protocol. Studies were
analyzed using a visual semiquantitative 5-point, 16-
segment American Heart Association scoring system
(14). For visual interpretation, first and second studies
were considered side by side, with the reader blinded
to treatment assignment for the 2 stress perfusion
studies. Scores in the basal mid-axis and distal short-
axis slices were summed to obtain a summed rest
score, a summed stress score, and a summed difference
score (14). The percentage of ischemic myocardium
was defined as the sum of the scores divided by 64,
which is a product of the 16 segments analyzed and
the worst uptake score of 4 (16).
First-pass perfusion images were also analyzed
using CAAS MRV CMR analysis software version
3.3 (Pie Medical Imaging B.V., Maastricht, the
Netherlands). Epicardial and endocardial contours
of the left ventricular myocardium for 3 short-axis
slices (basal, mid, and apical) were determined by
the software and manually corrected if needed to
acquire intensity over time curves, which were used
to measure the myocardial perfusion reserve index
(MPRI). The whole myocardial, subendocardial,
and subepicardial MPRI were calculated as the ratio of
stress/rest relative perfusion up-slope, corrected for left
ventricular cavity up-slope. The subendocardial and
subepicardial layers were automatically defined by the
software as the inner and outer 50% of the wall
thickness between the contoured myocardium. These
methods using quantitative up-slope curves used in
this study are reproducible techniques with high in-
terstudy and observer reproducibility (17,18).
Invasive CFR testing. Clinically indicated invasive
coronary reactivity testing (CRT) using the NHLBI–
sponsored WISE protocol to measure coronary mi-
crovascular and macrovascular endothelium-
dependent and nonendothelium-dependent function
(3,19,20) was available in a majority subset (n  13).
pecifically, coronary arterial flow reserve (CFR) was
easured by graded intracoronary adenosine injec-
ions of 18 g and 36 g to create maximal hyper-
emia, and flow in the proximal left anterior descend-
ing was measured with a Doppler flow wire (FloWire,
Volcano, San Diego, California). Graded doses of
intracoronary acetylcholine were used to test endothe-
lial function and determine coronary blood flow;
intracoronary nitroglycerin was used to assess smooth
muscle function.Statistical analysis. Randomized treatment compar-
sons were made according to intention-to-treat
rinciples using nonparametric statistics. Compar-
ng the ranolazine and placebo visits, we used the
riedman test of k-related samples or the Wilcoxon
igned-rank test for comparing 2 related samples. In
ome cases, a profile plot was used to compare changes
n CMR measurements (placebo/ranolazine). A trend
nalysis was applied using the orthogonal trend con-
rast coefficients. A mixed-effects model was used to
nalyze for carryover effect, which tests for influence
f one treatment over another. All tests of hypoth-
ses were 2 sided with a type I error rate of 0.05,
nd p value 0.05 was considered statistically
ignificant. All statistical analyses were done using
AS software (version 9.1, SAS Institute Inc.,
ary, North Carolina).
R E S U L T S
Patient characteristics. The baseline demographic
nd clinical characteristic data for the 20 women are
hown in Table 1. Despite current antianginal
herapy, all patients were symptomatic with angina at
he time of study enrollment; 95% had typical angina
n addition to 45% with shortness of breath, 30% with
alpitations, and 15% with nausea. Between the qual-
fying CMR and study entry (mean 10.2  8.5
onths), most patients had been started on beta-
locker, angiotensin-converting enzyme inhibitor, and
tatin therapy, as clinically indicated. The ranolazine/
lacebo interventions were well tolerated with 100%
tudy completion and no dropouts.
Angina results. Three of 5 SAQ subscale scores were
igher (better) on ranolazine compared with placebo,
ncluding significantly higher physical functioning,
ngina stability, and quality of life (Table 2). Treat-
ent satisfaction trended lower on ranolazine (p 
.058) (Table 2). There was no significant entry or
xit group differences in the DASI on ranolazine
ompared with placebo (8.6 [3.7 minimum, 11.5
aximum] METS vs. 8.9 [5.4 minimum, 12.1 max-
mum] METS, p  0.47). We found no carryover
ffect for SAQ subscales or CMR imaging variables
escribed in the following.
CMR results. We did not observe rest perfusion
abnormalities in any subjects. Specifically, only the
stress images had significant hypoperfusion abnor-
malities, which is reflected in the percentage of
ischemic myocardium, summed difference scores,
and MPRI scores reported in Tables 1 and 3.
Compared with placebo, treatment with ranolazine
resulted in group differences uniformly in the hy-
SAQ  Seattle Angin
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518pothesized direction by CMR; however, none were
statistically significant (Table 3). Notably, there was
a trend of higher mid-ventricular MPRI, an area of
highest CMR measurement reproducibility, on ra-
nolazine compared with placebo that approached
statistical significance (Table 3).
We next stratified the results according to base-
line (qualifying) CMR abnormality. Women with a
res on Ranolazine Versus Placebo
Ranolazine Placebo
Treatment Effect
(p Value)
g 91.7 (79.2, 97.9) 83.3 (66.6, 97.2) 0.046
75.0 (50.0, 100.0) 50.0 (25.0, 75.0) 0.008
80.0 (50.0, 100.0) 75.0 (60.0, 87.5) 0.197
tion 87.5 (75.0, 100.0) 93.8 (75.0, 100.0) 0.058
75.0 (60.4, 83.3) 66.7 (58.3, 75.0) 0.021
inimum, maximum). A higher SAQ score is better in each domain. The bold type
signiﬁcant p Values.
Table 1. Baseline Demographic and Clinical Variables (n  20)
Age, yrs, 57 11
Body mass index, kg/m2
Mean  SD 25.6 3.8
30 kg/m2 3 (15)
Race (non-Caucasian) 4 (20)
Tobacco use
Current 0 (0)
Former 10 (50)
Never 10 (50)
Hypertension 10 (50)
Hyperlipidemia 12 (60)
Family history of premature coronary
artery disease
14 (70)
Coronary reactivity testing 13 (65)
Baseline cardiac magnetic resonance
Percentage of ischemic myocardium 21.9 (16.8, 31.3)
Summed difference score 20.3 (15.6, 33.6)
Global MPRI 1.4 (1.2, 1.9)
Mid-ventricular MPRI 1.4 (1.2, 2.1)
Symptoms
Typical angina 19 (95)
Shortness of breath 9 (45)
Palpitations 6 (30)
Nausea 3 (15)
Left ventricular ejection fraction, % 71 6
Beta-blockers 14 (70)
Calcium channel blockers 4 (20)
Angiotensin-converting enzyme inhibitors 9 (45)
Angiotensin receptor blockers 3 (15)
Nitrates 9 (45)
Values are mean  SD, n (%), or median (minimum, maximum).
MPRI  myocardial perfusion reserve index.a Questionnaire.baseline MPRI 1.5 (lower perfusion reserve)
had a trend toward higher MPRI on ranolazine
compared with placebo (p  0.2), whereas those
women with an MPRI 1.5 did not (p  0.55)
(Fig. 3). Similar trends were observed for the visual
qualifying summed difference score (data not shown).
We next evaluated CMR results stratified by
SAQ angina response, defined as a change in SAQ
angina frequency of 0 (placebo/ranolazine). This
analysis demonstrated that among angina respond-
ers, MPRI trended toward being higher on ranola-
zine than on placebo (2.4 vs. 2.0, treatment effect
p  0.059); there were no group differences when
stratified by the other SAQ scores.
Subgroup analysis of the 13 women who under-
went clinically indicated invasive CRT demon-
strated that the subgroup with lower CFR (3.0)
had significant MPRI improvement on ranolazine
compared to women with CFR 3.0 ( in MPRI
placebo/ranolazine: 0.48 vs. 0.82, p  0.04) (Fig. 4).
D I S C U S S I O N
To our knowledge, this is the first controlled trial to
report an improvement in SAQ angina with rano-
lazine compared with placebo in women with signs
and symptoms of myocardial ischemia but no ob-
structive CAD. In this pilot trial, we also demon-
strated a possible anti-ischemic role of ranolazine as
a mechanism of action for its antianginal effects.
These data document approach feasibility and pro-
vide outcome variability estimates for planning a
definitive large clinical trial to evaluate the role of
ranolazine in women with MCD.
Evidence of both ischemia and angina predict
adverse cardiovascular events in women with and
without obstructive CAD (1,2,21–24). Ranolazine
has been established as an effective antianginal in
patients with obstructive CAD, and there is evidence
that it improves ischemia based on electrocardio-
graphic stress testing (4). A recent open-label, non-
randomized study suggested that ranolazine treatment
is associated with improvement in automated quanti-
tative analysis of single-photon emission computed
tomography images (25). Our results are consistent
with and extend these observations in a randomized,
controlled trial setting using quantitative estimates of
myocardial perfusion imaging and detailed measure-
ment of the improvements in the burden of angina for
women with evidence of MCD.
Sex differences in angina exist and likely affect
antianginal therapy. The CARISA (CombinationTable 2. SAQ Sco
Physical functionin
Angina stability
Angina frequency
Treatment satisfac
Quality of life
Values are median (m
indicates statisticallyAssessment of Ranolazine in Stable Angina) study
(
C
).
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519demonstrated that addition of ranolazine in women
had similar reductions in angina frequency and
nitroglycerin use as in men, although less improve-
ment in exercise testing–related angina (8). Analysis
from the MERLIN–TIMI 36 (Metabolic Effi-
ciency with Ranolazine for Less Ischemia in Non–
ST-Elevation Acute Coronary Syndromes–
Thrombolysis In Myocardial Infarction 36) study
showed that women had less obstructive CAD
compared with men, and women had a 29% reduc-
tion in recurrent ischemia on ranolazine compared
with placebo, a change that was not evident in men
(26). Given these previous findings and the hemody-
namic tolerability profile of ranolazine, we hypothe-
sized that women with evidence of MCD would
demonstrate angina improvement on therapy.
Our current study demonstrates that women with
angina, evidence of ischemia, and no obstructive
CAD have significant benefit from ranolazine com-
pared with placebo in the objective measure of SAQ
angina. We report that 3 of 5 SAQ measures were
significantly improved with ranolazine therapy.
Treatment satisfaction trended in a negative direc-
tion on ranolazine; this may have been due to the
play of chance, patient expectation that ranolazine
would provide a complete relief of angina, or,
alternatively, could be related to side effects of
ranolazine, although all subjects completed the
study with no dropouts. Of note, subjects continued
their routine medications while taking ranolazine.
Trials addressing the use of antianginal medications
in women are critical due to the growing burden of
ischemic heart disease; more than one-half of the 8.9
million patients in the United States are women with
chronic stable angina. Chronic stable angina is not
benign and not only portends significant morbidity
and mortality (22,26), it also leads to poor quality of
life (27). Although obstructive CAD is a prominent
cause of ischemic heart disease, women have a 2-fold
increase in normal coronaries (no obstructive disease
visible by traditional angiography) compared with
men in the setting of acute coronary syndrome, non–
ST-segment elevation and ST-segment elevation
myocardial infarction (19).
Women with angina often require multiple med-
ications for symptom control (19). Pharmacological
therapy for chronic stable angina for symptom relief
has centered on beta-blockers, calcium channel
blockers, and nitrates (28); these agents reduce
myocardial oxygen demand by reducing inotropy
and chronotropy, preload, and blood pressure. Al-
though effective in general, many patients experi-
ence breakthrough and refractory angina despitetreatment, and other times, these agents are not
tolerated because of their hemodynamic side effects.
Ranolazine, a piperazine derivative, is believed to
work on the ischemic myocardium via inhibition of
late inward Na current, which interrupts calcium
Ca2) overload in ischemic myocytes. Increased
a2 overload in the ischemic myocardium has been
linked to left ventricular diastolic dysfunction. Studies
have shown that ranolazine improves left ventricular
diastolic function in ischemic heart disease patients
(29,30). As an antianginal agent, ranolazine is partic-
ularly promising because it does not have significant
effects on heart rate and blood pressure.
Invasive CRT can be performed for a definitive
assessment of MCD in women with persistent angina
with no obstructive CAD (2,3,20). Current mecha-
nistic pathways for MCD include endothelial and
smooth muscle dysfunction due to oxidative and/or
inflammatory stress (31,32). Both abnormal coronary
vascular response to acetylcholine (i.e., failure to
dilate) and abnormal CFR predict adverse car-
diovascular outcomes in women (3,20). Previous
data indicate that invasive measures of coronary
reactivity correlate with CMR-measured perfu-
sion reserve (33,34). In our study, 13 of the 20
women had undergone CRT, and ranolazine
resulted in a significant improvement in myocar-
dial perfusion reserve in women with a baseline
CFR of 3.0. These data suggest that a large,
definitive clinical trial of ranolazine in this pop-
ulation should target subjects with low myocar-
dial perfusion reserve.
Study limitations. Our pilot study, by design, in-
cluded a small number of subjects for demonstra-
tion of approach feasibility and determination of
study outcome variability for sample size calcula-
tion. Our study is therefore limited with regard to
Table 3. Visual and Quantitative CMR Defects on Ranolazine ve
Ranolazine Placebo
Percentage of ischemic myocardium 11.7 (8.0, 19.3) 16.0 (8.6, 22.7
Summed difference score 10.2 (3.5, 15.2) 14.8 (5.5, 19.5
MPRI
Global 2.1 (2.2, 2.4) 1.9 (1.7, 2.5)
Mid-ventricular 2.4 (2.0, 2.8) 2.1 (1.7, 2.5)
Subendocardial (whole) 2.0 (1.7, 2.2) 1.8 (1.5, 2.3)
Subendocardial (mid-ventricular) 2.1 (1.7, 2.5) 1.9 (1.5, 2.3)
Subepicardial (whole) 2.3 (2.1, 2.6) 2.0 (1.8, 2.5)
Subepicardial (mid-ventricular) 2.6 (2.2, 3.0) 2.2 (1.9, 2.5)
Values are median (minimum, maximum). For summed difference score, lower
MPRI  myocardial perfusion reserve index (higher is better perfusion reserversus Placebo
Treatment Effect
(p Value)
) 0.64
) 0.82
0.66
0.074
0.66
1.0
0.18
0.18
is better.definitive statements regarding the role of ranola-
o
H
o
f
u
m
M
Vber indicates greater p
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520zine as anti-ischemic treatment of symptomatic
women with evidence of ischemia but no obstruc-
tive CAD. We minimized the influence of a carry-
ver effect by interjecting a 2-week washout period.
owever, the potential for influence on certain aspects
f our study design remain plausible including patient
amiliarity with the testing protocol, which remains
naccounted for in our data analysis. Also, although a
ajority of the enrolled women had invasive CRT,
Figure 3. MPRI on Ranolazine Versus Placebo According to Qua
Solid lines indicate subjects who had a higher myocardial perfusion
dashed lines indicate subjects who did not (n  11).
e (Placebo/Ranolazine) According to CFR in the Subset of
ry Reactivity Testing (n  13)
ronary ﬂow reserve (CFR) (2.5, n  5) and (2.6 to 3.0, n  6)
ater myocardial perfusion reserve index (MPRI) change (placebo/
to women with CFR 3.0 (n  2) (p  0.04). A higher MPRI num-9
erfusion.this did not include all subjects. The strengths of our
study include the use of a validated measure, the SAQ,
and core laboratory myocardial perfusion evaluation.
A potential limitation may be the visual segmental
scoring range of 0 to 4 for the semiquantitative
myocardial perfusion, which may exceed the visually
detectable grades of hypoperfusion; however, we also
used a quantitative myocardial perfusion reserve anal-
ysis. A final limitation is that although SAQ measures
chest pain and shortness of breath to evaluate angina,
many women with ischemia experience anginal equiv-
alents such as fatigue, indigestion, and weakness.
C O N C L U S I O N S
In women with angina, evidence of myocardial
ischemia, and no obstructive CAD, the data from
this pilot study suggest a role for ranolazine in
improving angina and ischemic myocardium. Our
data support the feasibility of our approach and
provide outcome variability data with which to plan
a larger, definitive, randomized trial comparing the
effectiveness of ranolazine as an antianginal and
anti-ischemic therapy in women with MCD.
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